{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:12:25Z","timestamp":1791252745720,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.clgc.2012.05.001","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T17:17:36Z","timestamp":1339521456000},"page":"232-238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Safety and Preliminary Efficacy Analysis of the mTOR Inhibitor Ridaforolimus in Patients With Taxane-Treated, Castration-Resistant Prostate Cancer"],"prefix":"10.1016","volume":"10","author":[{"given":"Robert J.","family":"Amato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Wilding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Bubley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Loewy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Haluska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell E.","family":"Gross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2012.05.001_bib1","series-title":"Cancer Facts and Figures 2010","year":"2010"},{"key":"10.1016\/j.clgc.2012.05.001_bib4","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2012.05.001_bib5","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2012.05.001_bib6","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.05.001_bib7","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/1535-7163.MCT-07-2408","article-title":"Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies","volume":"7","author":"Garcia","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clgc.2012.05.001_bib8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.urolonc.2009.03.023","article-title":"Mammalian target of rapamycin: a new target in prostate cancer","volume":"28","author":"Rai","year":"2010","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2012.05.001_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clgc.2012.05.001_bib10","doi-asserted-by":"crossref","first-page":"5389","DOI":"10.1158\/1078-0432.CCR-08-3007","article-title":"Concurrent and sequential administration of chemotherapy and the mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts","volume":"15","author":"Fung","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2012.05.001_bib11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1677\/erc.1.00835","article-title":"Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation","volume":"12","author":"Ghosh","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.clgc.2012.05.001_bib12","first-page":"3051","article-title":"Targeting AKT\/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model","volume":"118","author":"Kinkade","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clgc.2012.05.001_bib13","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/pros.21120","article-title":"Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by rheb in prostate cancer cell proliferation","volume":"70","author":"Kobayashi","year":"2010","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2012.05.001_bib14","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/pros.20752","article-title":"RAD001 (everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid","volume":"68","author":"Morgan","year":"2008","journal-title":"Prostate"},{"key":"10.1016\/j.clgc.2012.05.001_bib15","doi-asserted-by":"crossref","first-page":"7106","DOI":"10.1038\/onc.2008.318","article-title":"Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival","volume":"27","author":"Wang","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.clgc.2012.05.001_bib16","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/0008-5472.CAN-04-3137","article-title":"Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts","volume":"65","author":"Wu","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2012.05.001_bib17","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1158\/0008-5472.CAN-08-4385","article-title":"Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a PTEN-deficient mouse model of prostate cancer","volume":"69","author":"Zhang","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.clgc.2012.05.001_bib18","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nm1052","article-title":"MTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways","volume":"10","author":"Majumder","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.clgc.2012.05.001_bib19","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1517\/13543780802556485","article-title":"Deforolimus (AP23573) a novel mTOR inhibitor in clinical development","volume":"17","author":"Mita","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.clgc.2012.05.001_bib20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1200\/JCO.2007.12.0345","article-title":"Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies","volume":"26","author":"Mita","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.05.001_bib21","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1158\/1078-0432.CCR-08-2076","article-title":"A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies","volume":"15","author":"Hartford","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2012.05.001_bib22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2012.05.001_bib23","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.05.001_bib24","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1158\/1078-0432.CCR-05-0109","article-title":"Prostate cancer clinical trial end points: \u201cRECIST\u201ding a step backwards","volume":"11","author":"Scher","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2012.05.001_bib25","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1111\/j.1600-6143.2008.02430.x","article-title":"The effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer","volume":"8","author":"Chamie","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.clgc.2012.05.001_bib26","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1158\/0008-5472.CAN-04-3411","article-title":"Post-transcriptional regulation of the androgen receptor by mammalian target of rapamycin","volume":"65","author":"Cinar","year":"2005","journal-title":"Cancer Res"},{"issue":"18S)","key":"10.1016\/j.clgc.2012.05.001_bib27","article-title":"Rapamycin for androgen independent prostate cancer (AIPC)","volume":"24","author":"Sharef","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2012.05.001_bib28","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1016\/j.ejca.2009.05.033","article-title":"Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point?","volume":"45","author":"Ohorodnyk","year":"2009","journal-title":"Eur J Cancer"},{"issue":"15s","key":"10.1016\/j.clgc.2012.05.001_bib29","doi-asserted-by":"crossref","first-page":"TPS246","DOI":"10.1200\/jco.2010.28.15_suppl.tps246","article-title":"A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC)","volume":"28","author":"Emmenegger","year":"2010","journal-title":"J Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767312001139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767312001139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:21:59Z","timestamp":1761564119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767312001139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S1558767312001139"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2012.05.001","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Preliminary Efficacy Analysis of the mTOR Inhibitor Ridaforolimus in Patients With Taxane-Treated, Castration-Resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2012.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}